United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $3.68, $0.82 better than the analyst estimate of $2.86. Revenue for the quarter came in at $362 million versus the consensus estimate of $339.97 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.